文献速递贫血与红细胞疾病造血干细胞移植与细胞治疗

重型再生障碍性贫血需进行基因检测以优化造血细胞移植结局

Genetic testing in severe aplastic anemia is required for optimal hematopoietic cell transplant outcomes.
PubMed 文献 · Blood · 2022-01-01

对1989至2015年间接受造血细胞移植的732例获得性重型再生障碍性贫血患者进行外显子测序,在104个IBMFS相关基因中筛查胚系变异。48例(6.6%)存在未被识别的IBMFS,其移植后生存劣于获得性SAA(HR 2.13,95%CI 1.40-3.24,P=.0004),携带者生存与获得性SAA无差异。作者认为所有SAA患者诊断评估应包含基因检测以调整治疗方案。

要点

  • 732例接受HCT的获得性SAA患者中,6.6%存在未被识别的IBMFS。
  • 未被识别的IBMFS患者移植后生存劣于获得性SAA(HR 2.13)。
  • IBMFS基因致病变异携带者移植后生存与获得性SAA无显著差异。

核心结论

  • 在104个IBMFS相关基因中检出符合已知疾病合子模式的致病或可能致病变异的患者被认定为未被识别的IBMFS。
  • 未被识别的IBMFS患者移植后生存劣于获得性SAA,而携带者与获得性SAA生存无显著差异。
  • 作者认为基因检测应作为所有SAA患者诊断评估的一部分以调整治疗方案。

研究设计与样本

  • 对1989至2015年间因获得性SAA接受造血细胞移植的732例患者进行外显子测序,分析104个IBMFS相关基因的胚系变异。
  • 将符合已知疾病合子模式的致病或可能致病变异患者认定为未被识别的IBMFS;常染色体隐性基因单个致病或可能致病变异或女性X连锁隐性致病或可能致病变异者为携带者。
  • 采用Cox比例风险模型进行生存分析,随访至2017年。

主要发现

  • 121例患者中检出42个基因的113个致病或可能致病单核苷酸变异或小插入/缺失及10个拷贝数变异。
  • 91例患者检出105个计算机预测有害的意義未明变异(dVUS)。
  • 48例(6.6%)存在未被识别的IBMFS(其中33%为成人),73例(10%)为携带者。
  • dVUS与获得性SAA之间未观察到生存差异。
  • 与获得性SAA(无致病或可能致病变异)相比,未被识别的IBMFS患者移植后生存更差(HR 2.13;95%CI 1.40-3.24;P=.0004),携带者无显著差异(HR 0.96;95%CI 0.62-1.50;P=.86)。

关键数值与推荐

  • 在减少强度预处理患者(n=448)中分析结果相似(IBMFS的HR=2.39;P=.01)。
  • 未被识别的IBMFS的额外死亡风险归因于器官衰竭死亡(HR=4.88;P<.0001)。

临床怎么用

  • 作者认为基因检测应作为所有SAA患者诊断评估的一部分,以调整治疗方案。
  • IBMFS基因致病变异携带者可遵循获得性SAA的HCT方案。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Patients with severe aplastic anemia (SAA) can have an unrecognized inherited bone marrow failure syndrome (IBMFS) because of phenotypic heterogeneity. We curated germline genetic variants in 104 IBMFS-associated genes from exome sequencing performed on 732 patients who underwent hematopoietic cell transplant (HCT) between 1989 and 2015 for acquired SAA. Patients with pathogenic or likely pathogenic (P/LP) variants fitting known disease zygosity patterns were deemed unrecognized IBMFS. Carriers were defined as patients with a single P/LP variant in an autosomal recessive gene or females with an X-linked recessive P/LP variant. Cox proportional hazard models were used for survival analysis with follow-up until 2017. We identified 113 P/LP single-nucleotide variants or small insertions/deletions and 10 copy number variants across 42 genes in 121 patients. Ninety-one patients had 105 in silico predicted deleterious variants of uncertain significance (dVUS). Forty-eight patients (6.6%) had an unrecognized IBMFS (33% adults), and 73 (10%) were carriers. No survival difference between dVUS and acquired SAA was noted. Compared with acquired SAA (no P/LP variants), patients with unrecognized IBMFS, but not carriers, had worse survival after HCT (IBMFS hazard ratio [HR], 2.13; 95% confidence interval[CI], 1.40-3.24; P = .0004; carriers HR, 0.96; 95% CI, 0.62-1.50; P = .86). Results were similar in analyses restricted to patients receiving reduced-intensity conditioning (n = 448; HR IBMFS = 2.39; P = .01). The excess mortality risk in unrecognized IBMFS attributed to death from organ failure (HR = 4.88; P < .0001). Genetic testing should be part of the diagnostic evaluation for all patients with SAA to tailor therapeutic regimens. Carriers of a pathogenic variant in an IBMFS gene can follow HCT regimens for acquired SAA.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. McReynolds LJ, Rafati M, Wang Y, et al. Genetic testing in severe aplastic anemia is required for optimal hematopoietic cell transplant outcomes. Blood. 2022. PMID: 35776903. doi:10.1182/blood.2022016508

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。